Life Sciences

Pfizer to settle Bextra, Celebrex claims for $894M

Pharma Compliance Alert, October 22, 2008

Pfizer has agreed in principle to pay $894 million to settle all lawsuits related to its non-steroidal anti-inflammatory drugs Bextra and Celebrex, according to a company release.

The settlement covers more than 90% of the personal injury lawsuits filed by patients who claim the drugs caused a heart attack, stroke, or other injury. The settlement also resolves payer class action consumer fraud cases involving Bextra and Celebrex in which plaintiffs allege economic loss relating to the promotion of these medications.

Pfizer also reached an agreement to settle claims by 33 states and the District of Columbia relating to alleged marketing practices for Bextra.


0 comments on “Pfizer to settle Bextra, Celebrex claims for $894M


    Healthcare Life Safety Compliance
  • Healthcare Life Safety Compliance

    Created exclusively for healthcare facility managers, plant operations professionals, and directors of engineering, this...

  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Healthcare Marketing Advisor

    Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...

Most Popular